$RXST
RxSight, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024090770 Filed on August 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $35.31M $34.89M
YoY Change 59.08% 67.65%
Cost Of Revenue $10.09M $10.64M
YoY Change 19.2% 20.94%
Gross Profit $25.22M $24.25M
YoY Change 83.67% 101.83%
Gross Profit Margin 71.42% 69.51%
Selling, General & Admin $25.61M $24.29M
YoY Change 33.78% 33.08%
% of Gross Profit 101.54% 100.17%
Research & Development $8.838M $8.291M
YoY Change 24.46% 12.83%
% of Gross Profit 35.04% 34.19%
Depreciation & Amortization $1.141M $820.0K
YoY Change 0.97% -20.39%
% of Gross Profit 4.52% 3.38%
Operating Expenses $34.45M $32.58M
YoY Change 31.26% 27.08%
Operating Profit -$9.226M -$8.333M
YoY Change -26.26% -38.84%
Interest Expense $5.000K $6.000K
YoY Change -97.83% -97.13%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.325M -$6.063M
YoY Change -49.0% -56.0%
Income Tax $13.00K $16.00K
% Of Pretax Income
Net Earnings -$6.338M -$6.079M
YoY Change -48.95% -55.96%
Net Earnings / Revenue -17.95% -17.42%
Basic Earnings Per Share -$0.16 -$0.16
Diluted Earnings Per Share -$0.16 -$0.16
COMMON SHARES
Basic Shares Outstanding 39.68M 37.20M
Diluted Shares Outstanding 39.79M 38.46M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $237.1M $233.3M
YoY Change 79.77% 58.6%
Cash & Equivalents $16.72M $24.45M
Short-Term Investments $220.4M $208.8M
Other Short-Term Assets $2.607M $2.773M
YoY Change 37.21% 31.3%
Inventory $21.67M $19.44M
Prepaid Expenses
Receivables $25.37M $25.72M
Other Receivables $0.00 $0.00
Total Short-Term Assets $286.8M $281.2M
YoY Change 70.75% 55.85%
LONG-TERM ASSETS
Property, Plant & Equipment $12.24M $12.44M
YoY Change 19.28% -9.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $213.0K $303.0K
YoY Change 55.47% -72.68%
Total Long-Term Assets $23.70M $24.28M
YoY Change 70.47% 63.85%
TOTAL ASSETS
Total Short-Term Assets $286.8M $281.2M
Total Long-Term Assets $23.70M $24.28M
Total Assets $310.5M $305.5M
YoY Change 70.73% 56.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.581M $5.095M
YoY Change 11.6% 27.47%
Accrued Expenses $18.03M $14.50M
YoY Change 21.82% 16.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $27.00K $26.00K
YoY Change -66.67%
Total Short-Term Liabilities $22.64M $19.62M
YoY Change 19.51% 18.43%
LONG-TERM LIABILITIES
Long-Term Debt $114.0K $121.0K
YoY Change -99.38%
Other Long-Term Liabilities $10.46M $10.55M
YoY Change 646.86% 449.92%
Total Long-Term Liabilities $10.57M $10.67M
YoY Change 655.0% -50.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.64M $19.62M
Total Long-Term Liabilities $10.57M $10.67M
Total Liabilities $33.21M $30.29M
YoY Change 63.02% -20.44%
SHAREHOLDERS EQUITY
Retained Earnings -$616.2M -$609.8M
YoY Change 5.24% 6.42%
Common Stock $40.00K $40.00K
YoY Change 11.11% 14.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $277.3M $275.2M
YoY Change
Total Liabilities & Shareholders Equity $310.5M $305.5M
YoY Change 70.73% 56.46%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$6.338M -$6.079M
YoY Change -48.95% -55.96%
Depreciation, Depletion And Amortization $1.141M $820.0K
YoY Change 0.97% -20.39%
Cash From Operating Activities $650.0K -$4.027M
YoY Change -108.15% -46.63%
INVESTING ACTIVITIES
Capital Expenditures $1.103M $1.523M
YoY Change 69.69% -16.46%
Acquisitions
YoY Change
Other Investing Activities -$8.157M -$114.1M
YoY Change -145.49% -1935.35%
Cash From Investing Activities -$9.260M -$115.6M
YoY Change -153.62% -2731.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 878.0K 111.5M
YoY Change -110.66% 12411.0%
NET CHANGE
Cash From Operating Activities 650.0K -4.027M
Cash From Investing Activities -9.260M -115.6M
Cash From Financing Activities 878.0K 111.5M
Net Change In Cash -7.732M -8.199M
YoY Change -836.38% 262.79%
FREE CASH FLOW
Cash From Operating Activities $650.0K -$4.027M
Capital Expenditures $1.103M $1.523M
Free Cash Flow -$453.0K -$5.550M
YoY Change -94.75% -40.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001111485
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet
CY2023Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20240630#LeaseLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20240630#LeaseLiabilitiesCurrent
CY2024Q2 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20240630#LeaseLiabilitiesCurrent
CY2023Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20240630#LeaseLiabilitiesCurrent
CY2024Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20240630#LeaseLiabilitiesNoncurrent
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20240630#LeaseLiabilitiesNoncurrent
CY2024Q2 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20240630#LeaseLiabilitiesNoncurrent
CY2023Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20240630#LeaseLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40690
dei Entity Registrant Name
EntityRegistrantName
RxSIGHT, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3268801
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Columbia
dei Entity Address City Or Town
EntityAddressCityOrTown
Aliso Viejo
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92656
dei City Area Code
CityAreaCode
949
dei Local Phone Number
LocalPhoneNumber
521-7830
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
RXST
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39682804
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24445000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9692000
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
208839000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
117490000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
25723000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
20281000
CY2024Q2 us-gaap Inventory Net
InventoryNet
19443000
CY2023Q4 us-gaap Inventory Net
InventoryNet
17421000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2773000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3523000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
281223000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
168407000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12444000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10841000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10818000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2444000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
711000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
711000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
303000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
147000
CY2024Q2 us-gaap Assets
Assets
305499000
CY2023Q4 us-gaap Assets
Assets
182550000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5095000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3863000
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13787000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
15239000
CY2024Q2 rxst Lease Liabilities Current
LeaseLiabilitiesCurrent
736000
CY2023Q4 rxst Lease Liabilities Current
LeaseLiabilitiesCurrent
1801000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
19618000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20903000
CY2024Q2 rxst Lease Liabilities Noncurrent
LeaseLiabilitiesNoncurrent
10674000
CY2023Q4 rxst Lease Liabilities Noncurrent
LeaseLiabilitiesNoncurrent
1211000
CY2024Q2 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
0
CY2023Q4 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
74000
CY2024Q2 us-gaap Liabilities
Liabilities
30292000
CY2023Q4 us-gaap Liabilities
Liabilities
22188000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39617334
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39617334
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36139513
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36139513
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
40000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
36000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
885104000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
754971000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-118000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-609819000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-594640000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
275207000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
160362000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
305499000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
182550000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34887000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20810000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
64399000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38299000
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10637000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8795000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
19464000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
15919000
CY2024Q2 us-gaap Gross Profit
GrossProfit
24250000
CY2023Q2 us-gaap Gross Profit
GrossProfit
12015000
us-gaap Gross Profit
GrossProfit
44935000
us-gaap Gross Profit
GrossProfit
22380000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24292000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18239000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
47616000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34492000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8291000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7401000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16322000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14608000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
32583000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
25640000
us-gaap Operating Expenses
OperatingExpenses
63938000
us-gaap Operating Expenses
OperatingExpenses
49100000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8333000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13625000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19003000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26720000
CY2024Q2 us-gaap Interest Expense
InterestExpense
6000
CY2023Q2 us-gaap Interest Expense
InterestExpense
1568000
us-gaap Interest Expense
InterestExpense
11000
us-gaap Interest Expense
InterestExpense
3075000
CY2024Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
2276000
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
1777000
us-gaap Interest And Other Income
InterestAndOtherIncome
3860000
us-gaap Interest And Other Income
InterestAndOtherIncome
3168000
CY2024Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-362000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-362000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6063000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13778000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15154000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26989000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
27000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6079000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13804000
us-gaap Net Income Loss
NetIncomeLoss
-15179000
us-gaap Net Income Loss
NetIncomeLoss
-27016000
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-64000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-65000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-109000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
19000
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
3000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-65000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-64000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-113000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
22000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6144000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13868000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15292000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26994000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.4
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.4
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.4
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.4
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38455955
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38455955
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34498265
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34498265
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37649521
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37649521
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33075585
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33075585
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
160362000
CY2024Q1 rxst Shares Issued For The Exercise Of Stock Options And Vesting Of Restricted Stock Units Amount
SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
10153000
CY2024Q1 rxst Shares Redeemed For Employee Tax With Holdings Amount
SharesRedeemedForEmployeeTaxWithHoldingsAmount
-2134000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4696000
CY2024Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-45000
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-3000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-9100000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
163929000
CY2024Q2 rxst Shares Issued For The Exercise Of Stock Options And Vesting Of Restricted Stock Units Amount
SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
3103000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6105000
CY2024Q2 rxst Shares Issued For The Employee Stock Purchase Plan Amount
SharesIssuedForTheEmployeeStockPurchasePlanAmount
737000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
107477000
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-64000
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6079000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
275207000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
89902000
CY2023Q1 rxst Shares Issued For The Exercise Of Stock Options And Vesting Of Restricted Stock Units Amount
SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
761000
CY2023Q1 rxst Shares Redeemed For Employee Tax With Holdings Amount
SharesRedeemedForEmployeeTaxWithHoldingsAmount
-337000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3295000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
53600000
CY2023Q1 rxst Issuance Of Common Stock In At The Market Offerings Net Of Issuance Costs Amount
IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount
10914000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
84000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-13212000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
145009000
CY2023Q2 rxst Shares Issued For The Exercise Of Stock Options And Vesting Of Restricted Stock Units Amount
SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
2599000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3955000
CY2023Q2 rxst Shares Issued For The Employee Stock Purchase Plan Amount
SharesIssuedForTheEmployeeStockPurchasePlanAmount
536000
CY2023Q2 rxst Issuance Of Common Stock In At The Market Offerings Net Of Issuance Costs Amount
IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount
18957000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-65000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13804000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
157188000
us-gaap Profit Loss
ProfitLoss
-15179000
us-gaap Profit Loss
ProfitLoss
-27016000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1927000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1944000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
33000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
85000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
283000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-362000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3578000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2953000
us-gaap Share Based Compensation
ShareBasedCompensation
10801000
us-gaap Share Based Compensation
ShareBasedCompensation
7250000
us-gaap Inventory Write Down
InventoryWriteDown
167000
us-gaap Inventory Write Down
InventoryWriteDown
14000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5441000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2338000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2189000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3124000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-673000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-868000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
789000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1324000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1339000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2009000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13336000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25310000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3490000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2570000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
119000000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
115000000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
206881000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
156400000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-91371000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-43970000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
20000000
rxst Repayment Of Term Loan
RepaymentOfTermLoan
0
rxst Repayment Of Term Loan
RepaymentOfTermLoan
40000000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
108100000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
54050000
rxst Proceeds From Issuance Of Common Stock In At The Market Offerings
ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings
0
rxst Proceeds From Issuance Of Common Stock In At The Market Offerings
ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings
30496000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13993000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3896000
rxst Payments For Employee Taxes Related To Stock Compensation
PaymentsForEmployeeTaxesRelatedToStockCompensation
-2133000
rxst Payments For Employee Taxes Related To Stock Compensation
PaymentsForEmployeeTaxesRelatedToStockCompensation
-337000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
38000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
82000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
377000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
602000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
80000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1225000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
119465000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
66196000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-4000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14754000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3081000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10402000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12595000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25156000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9514000
us-gaap Operating Lease Payments
OperatingLeasePayments
1128000
us-gaap Operating Lease Payments
OperatingLeasePayments
1107000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
24000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
12000
rxst Interest Paid On Financing Leases
InterestPaidOnFinancingLeases
11000
rxst Interest Paid On Financing Leases
InterestPaidOnFinancingLeases
7000
rxst Interest Paid On Term Loan
InterestPaidOnTermLoan
0
rxst Interest Paid On Term Loan
InterestPaidOnTermLoan
3240000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
9060000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
19000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
rxst Operating Lease Obligations Incurred
OperatingLeaseObligationsIncurred
9060000
rxst Operating Lease Obligations Incurred
OperatingLeaseObligationsIncurred
0
rxst Finance Lease Obligations Incurred
FinanceLeaseObligationsIncurred
19000
rxst Finance Lease Obligations Incurred
FinanceLeaseObligationsIncurred
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
229000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
408000
rxst Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
392000
rxst Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
187000
rxst Reclassification Of Deferred Cost
ReclassificationOfDeferredCost
-768000
rxst Reclassification Of Deferred Cost
ReclassificationOfDeferredCost
-1075000
rxst Number Of Wholly Owned Subsidiaries
NumberOfWhollyOwnedSubsidiaries
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
233200000
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
127200000
CY2024Q2 rxst Operating Income Loss1
OperatingIncomeLoss1
8300000
CY2023Q2 rxst Operating Income Loss1
OperatingIncomeLoss1
13600000
rxst Operating Income Loss1
OperatingIncomeLoss1
19000000
rxst Operating Income Loss1
OperatingIncomeLoss1
26700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:18pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of consolidated financial statements in conformity with GAAP requires management to make informed estimates, judgments and assumptions that affect the reported amounts in the condensed consolidated financial statements and disclosures in the accompanying notes as of the date of the accompanying condensed consolidated financial statements. On an on-going basis, management evaluates the most critical estimates and assumptions for continued reasonableness. Actual results may differ materially from the estimates used in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the accompanying condensed consolidated financial statements under different assumptions or conditions.</span></p>
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
99000000
CY2023 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
10000000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:18pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company’s policy is to invest cash in institutional money market funds and marketable securities of the U.S. government to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and short-term investments in money market funds and U.S. treasury bills. A portion of the Company's operating cash is held in accounts in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limits; however, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. The Company has not experienced material losses on cash equivalents and short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:18pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s products require approval from the FDA and foreign regulatory agencies before commercial sales can commence. There can be no assurance that the Company’s products will receive any of these required</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approvals. The denial or delay of such approvals may have a material adverse impact on the Company’s business and may impact business in the future. In addition, after approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the device approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:18pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of the Company's products, product liability and the need to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:18pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to the risks related to global lead times, particularly in Europe and Asia, leading to a supply interruption from the Company's suppliers. In addition, the Company is currently experiencing inflation and longer lead times and limited availability in its supply chain for certain components and has continued exposure to price and supply risk related to anticipated purchases of certain commodities, materials and products used in its business.</span></p>
rxst Accounts Receivable Percentage
AccountsReceivablePercentage
0.10
CY2023 rxst Accounts Receivable Percentage
AccountsReceivablePercentage
0.10
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34887000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20810000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
64399000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38299000
CY2023Q4 rxst Deferred Revenue1
DeferredRevenue1
-1888000
CY2022Q4 rxst Deferred Revenue1
DeferredRevenue1
-1193000
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
1949000
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
1391000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
1707000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
1233000
CY2024Q2 rxst Deferred Revenue1
DeferredRevenue1
-2130000
CY2023Q2 rxst Deferred Revenue1
DeferredRevenue1
-1351000
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
11327000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8092000
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
5313000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
5680000
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
3371000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
4145000
CY2024Q2 us-gaap Inventory Gross
InventoryGross
20011000
CY2023Q4 us-gaap Inventory Gross
InventoryGross
17917000
CY2024Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
568000
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
496000
CY2024Q2 us-gaap Inventory Net
InventoryNet
19443000
CY2023Q4 us-gaap Inventory Net
InventoryNet
17421000
CY2024Q2 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
5000000
CY2023Q4 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
4400000
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
227825000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
121965000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
Stock option awards are granted with an exercise price of no less than 100% of estimated fair market value on the date of grant. Time based awards generally vest over four years as follows, subject to the optionee’s continuing service: (i) one fourth of the total number of shares vest and become exercisable on the one-year anniversary and then 1/48th of the total number of shares subject to the option vest and become exercisable on each monthly anniversary thereafter for the remaining three years, or (ii) 1/48th of the total number of shares subject to the option vest and become exercisable each month over four years.
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6777404
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.02
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M3D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
799502
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
55.89
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1258874
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.53
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
62995
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
10236
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
4.57
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6244801
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.99
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M10D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3623940
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.23
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y5M12D
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
15300000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
8300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.651
rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.042
rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.041
rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife
P6Y
rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend Yield
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend Yield
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield
0
rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue
55.93
rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue
15.26
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8385548
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8364218
CY2022Q2 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P34M
CY2022Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2025-03-31
CY2022Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
11410
CY2023Q2 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
5319
CY2023Q2 us-gaap Lessee Operating Sublease Option To Terminate
LesseeOperatingSubleaseOptionToTerminate
On August 1, 2024 the sublease was cancelled.
CY2024Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
10800000
CY2024Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
200000
CY2024Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1400000
CY2024Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1600000
CY2024Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1800000
CY2024Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1800000
CY2024Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
4000000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10818000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2444000
CY2024Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
142000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
156000
CY2024Q2 rxst Total Lease Assets
TotalLeaseAssets
10960000
CY2023Q4 rxst Total Lease Assets
TotalLeaseAssets
2600000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
710000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1764000
CY2024Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
26000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
37000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10553000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1093000
CY2024Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
121000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
118000
CY2024Q2 rxst Total Lease Liabilities
TotalLeaseLiabilities
11410000
CY2023Q4 rxst Total Lease Liabilities
TotalLeaseLiabilities
3012000
CY2024Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
5000
CY2023Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
11000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
7000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1004000
CY2024Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
22000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2434000
CY2024Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
46000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2637000
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
46000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2782000
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
46000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2871000
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
39000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2954000
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
3308000
CY2024Q2 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
0
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17990000
CY2024Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
199000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6727000
CY2024Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
52000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
11263000
CY2024Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
147000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y6M29D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M8D
CY2024Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P4Y4M6D
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P4Y4M13D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.144
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.104
CY2024Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.144
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.14
us-gaap Legal Fees
LegalFees
0
CY2023 us-gaap Legal Fees
LegalFees
0

Files In Submission

Name View Source Status
0000950170-24-090770-index-headers.html Edgar Link pending
0000950170-24-090770-index.html Edgar Link pending
0000950170-24-090770.txt Edgar Link pending
0000950170-24-090770-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img74569629_0.jpg Edgar Link pending
img74569629_1.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
img74569629_2.jpg Edgar Link pending
img74569629_3.jpg Edgar Link pending
img74569629_4.jpg Edgar Link pending
img74569629_5.jpg Edgar Link pending
img74569629_6.jpg Edgar Link pending
img74569629_7.jpg Edgar Link pending
img75493150_0.jpg Edgar Link pending
img75493150_1.jpg Edgar Link pending
img75493150_2.jpg Edgar Link pending
img76416671_0.jpg Edgar Link pending
img77340192_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rxst-20240630.htm Edgar Link pending
rxst-20240630.xsd Edgar Link pending
rxst-ex10_1.htm Edgar Link pending
rxst-ex10_2.htm Edgar Link pending
rxst-ex10_3.htm Edgar Link pending
rxst-ex10_4.htm Edgar Link pending
rxst-ex10_5.htm Edgar Link pending
rxst-ex10_6.htm Edgar Link pending
rxst-ex31_1.htm Edgar Link pending
rxst-ex31_2.htm Edgar Link pending
rxst-ex32_1.htm Edgar Link pending
rxst-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
rxst-20240630_htm.xml Edgar Link completed